Hospital News· SinomedTrip Team
World-First Trial: PUMCH Proves New Drug Combination Nearly Doubles Response Rates in Aplastic Anemia
PUMCH's hematology team published the first-ever randomized trial showing luspatercept plus cyclosporine achieves 79% response rates in non-transfusion-dependent aplastic anemia — nearly double the standard treatment, especially in elderly patients.
Read More
